1. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60(4):657–64.

   Article CAS  Google Scholar 

2. Meola G, Cardani R. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. Neurol Sci. 2017;38(4):535–46.

   Article  Google Scholar 

3. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, et al. The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes. Int J Cardiol. 2013;168(2):1147–53.

   Article CAS  Google Scholar 

4. Wenninger S, Montagnese F, Schoser B. Core clinical phenotypes in myotonic dystrophies. Front Neurol. 2018;9:303.

   Article  Google Scholar 

5. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord. 2003;13(10):813–21.

   Article CAS  Google Scholar 

6. Romeo V, Pegoraro E, Ferrati C, Squarzanti F, Soraru G, Palmieri A, et al. Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol. 2010;257(8):1246–55.

   Article  Google Scholar 

7. Meola G, Sansone V. A newly-described myotonic disorder (proximal myotonic myopathy--PROMM): personal experience and review of the literature. Ital J Neurol Sci. 1996;17(5):347–53.

   Article CAS  Google Scholar 

8. Meola G, Sansone V, Radice S, Skradski S, Ptacek L. A family with an unusual myotonic and myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): a challenge for future molecular studies. Neuromuscul Disord. 1996;6(3):143–50.

   Article CAS  Google Scholar 

9. Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Otto M, Heine R, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology. 1994;44(8):1448–52.

   Article CAS  Google Scholar 

10. Thornton CA, Griggs RC, Moxley RT 3rd. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol. 1994;35(3):269–72.

    Article CAS  Google Scholar 

11. Udd B, Krahe R, Wallgren-Pettersson C, Falck B, Kalimo H. Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord. 1997;7(4):217–28.

    Article CAS  Google Scholar 

12. Meola G, Biasini F, Valaperta R, Costa E, Cardani R. Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach. J Neurol. 2017;264(8):1705–14.

    Article  Google Scholar 

13. Bugiardini E, Rivolta I, Binda A, Soriano Caminero A, Cirillo F, Cinti A, et al. SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscul Disord. 2015;25(4):301–7.

    Article CAS  Google Scholar 

14. Cardani R, Giagnacovo M, Botta A, Rinaldi F, Morgante A, Udd B, et al. Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J Neurol. 2012;259(10):2090–9.

    Article CAS  Google Scholar 

15. Logigian EL, Ciafaloni E, Quinn LC, Dilek N, Pandya S, Moxley RT 3rd, et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve. 2007;35(4):479–85.

    Article  Google Scholar 

16. Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, Koch MC, et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve. 2004;29(2):275–81.

    Article  Google Scholar 

17. Pisani V, Panico MB, Terracciano C, Bonifazi E, Meola G, Novelli G, et al. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle Nerve. 2008;38(5):1405–11.

    Article  Google Scholar 

18. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology. 2003;60(11):1854–7.

    Article CAS  Google Scholar 

19. Tohgi H, Kawamorita A, Utsugisawa K, Yamagata M, Sano M. Muscle histopathology in myotonic dystrophy in relation to age and muscular weakness. Muscle Nerve. 1994;17(9):1037–43.

    Article CAS  Google Scholar 

20. Harper PS, van Engelen BG, Eymard B, Rogers M, Wilcox D. 99th ENMC international workshop: myotonic dystrophy: present management, future therapy. 9–11 November 2001, Naarden, The Netherlands. Neuromuscul Disord. 2002;12(6):596–9.

    Article CAS  Google Scholar 

21. Dubowitz VS, Sewry CA, Oldfors A. In: Dubowitz VS, Sewry CA, Oldfors A, editors. Histological and Histochemical Changes. 4th ed. Oxford: Saunders Elsevier; 2013.

    Google Scholar 

22. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;68(4):799–808.

    Article CAS  Google Scholar 

23. Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992;255(5049):1256–8.

    Article CAS  Google Scholar 

24. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293(5531):864–7.

    Article CAS  Google Scholar 

25. Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW. Genetic mapping of a second myotonic dystrophy locus. Nat Genet. 1998;19(2):196–8.

    Article CAS  Google Scholar 

26. Thornton CA, Wang E, Carrell EM. Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev. 2017;44:135–40.

    Article CAS  Google Scholar 

27. Sellier C, Cerro-Herreros E, Blatter M, Freyermuth F, Gaucherot A, Ruffenach F, et al. rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences. Nat Commun. 2018;9(1):2009.

    Article  Google Scholar 

28. Logigian EL, Martens WB, RTt M, McDermott MP, Dilek N, Wiegner AW, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. 2010;74(18):1441–8.

    Article CAS  Google Scholar 

Download references